[Clinical evaluation of tulobuterol patch in patients with mild or moderate persistent bronchial asthma-effects of long-term treatment on airway inflammation and hypersensitivity].
[Clinical evaluation of tulobuterol patch in patients with mild or moderate persistent bronchial asthma-effects of long-term treatment on airway inflammation and hypersensitivity].
复制标题
妥洛特罗贴剂治疗轻中度持续性支气管哮喘的临床评价——长期治疗对气道炎症和过敏反应的影响
DOI：
--
复制
发表时间：
2004
期刊：
影响因子：
--
通讯作者：
S. Tachikawa
中科院分区：
文献类型：
--
作者：
T. Horiguchi;R. Kondo;Junichi Miyazaki;Hiroshi Torigoe;S. Tachikawa
妥洛特罗透皮治疗系统（TTS）是世界上第一个商业化的妥洛特罗透皮制剂，一种β-2兴奋剂，每天使用一次，可以保持有效的血液妥洛特罗水平24小时。在本研究中，共有36例轻度持续性（第2步）或中度持续性（第3步）支气管哮喘的成人患者，其中19例使用吸入性类固醇，17例未使用妥洛特罗TTS一年，并接受每日一次呼气峰流速（PEF）测量。在研究开始后6个月和1年评价外周血嗜酸性粒细胞计数、血清嗜酸性粒细胞阳离子蛋白（ECP）水平和气道反应性（Dmin）。PEF表现出显着改善，在6个月和1年的患者治疗或不吸入类固醇，而血清ECP显着改善，只有在患者吸入类固醇。未使用吸入性类固醇的患者在6个月或1年时未表现出Dmin显著加重：妥洛特罗TTS治疗1年似乎未引起快速耐受。使用吸入性类固醇的患者在6个月和1年时Dmin的显著改善表明吸入性类固醇在控制气道炎症方面提供了有益的作用。妥洛特罗TTS被认为对改善支气管哮喘患者的生活质量（QOL）非常有益，因为其不良反应（包括心悸和寒战）的发生率显著低于口服制剂，因为其显著改善肺功能和气道阻塞症状，即使重复使用后也不会增加气道反应性，并且因为其使用简单并且提供优异的临床功效。
The tulobuterol transdermal therapeutic system (TTS) is the world's first commercially available transdermal preparation of tulobuterol, a beta-2 stimulant, that can maintain effective blood tulobuterol levels for 24 hours when applied once daily. In the present study, a total of 36 adult patients with mildly persistent (Step 2) or moderately persistent (Step 3) bronchial asthma 19 who were using inhalational steroids and 17 who were not used tulobuterol TTS for one year and underwent measurement of peak expiratory flow (PEF) once daily. Peripheral eosinophil count, serum eosinophil cationic protein (ECP) level and airway responsiveness (Dmin) were evaluated at 6 months and 1 year after the start of the study. PEF exhibited significant improvements at 6 months and 1 year in patients treated with or without inhalational steroids, while serum ECP was improved significantly only in the patients on inhalational steroids. Patients not using inhalational steroids exhibited no significant exacerbation of Dmin at either 6 months or 1 year: One-year treatment with tulobuterol TTS did not appear to cause tachyphylaxis. The significant improvements in Dmin at 6 months and 1 year in the patients using inhalational steroids suggested that inhalational steroids offer beneficial effects in controlling airway inflammation. Tulobuterol TTS is considered quite beneficial in improving quality of life (QOL) in patients with bronchial asthma because its incidence of adverse effects including palpitations and shivering is significantly lower than those of oral preparations, because of its remarkable improvement of pulmonary function and symptoms of airway obstruction without increasing airway responsiveness even after repeated use, and because it is simple to use and offers excellent clinical efficacy.